Systems biology of pro-angiogenic therapies targeting the VEGF system

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 2, Issue 6, 2010, Pages 694-707

  Gabhann, Feilim Mac ^a   Qutub, Amina A ^b   Annex, Brian H ^c   Popel, Aleksander S ^b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CELL COMMUNICATION; CORONARY ARTERY DISEASE; GENETICS; HUMAN; METABOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RNA INTERFERENCE; SYSTEMS BIOLOGY;

CELL COMMUNICATION; CORONARY ARTERY DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA INTERFERENCE; SYSTEMS BIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79952199070     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.92     Document Type: Article

References (105)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, et al. Heart disease and stroke statistics- 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e181.
2. Hughes GC, Annex BH. Angiogenic therapy for coronary artery and peripheral arterial disease. Expert Rev Cardiovasc Ther 2005, 3(3):521-535.
3. Allen KB, Dowling RD, Angell WW, Gangahar DM, Fudge TL, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann Thorac Surg 2004, 77(4):1228-1234.
4. Hughes GC, Abdel-aleem S, Biswas SS, Landolfo KP, Lowe JE. Transmyocardial laser revascularization: experimental and clinical results. Can J Cardiol 1999, 15(7):797-806.
5. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, et al. Comparative evaluation of long-term clinical efficacy with catheter-based percutaneous intramyocardial autologous bone marrow cell implantation versus laser myocardial revascularization in patients with severe coronary artery disease.AmHeart J 2007, 154(5):982.e1-982.e6.
6. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003, 107(18):2294-2302.
7. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007, 28(24):2998-3005.
8. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003, 107(10):1359-1365.
9. Losordo DW, Vale PR, Hendel RC,Milliken CE, Fortuin FD, et al. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105(17):2012-2018.
10. Rajagopalan S, Mohler ER, 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108(16):1933-1938.
11. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105(11):1291-1297.
12. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, et al. A randomized, doubleblind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003, 42(8):1339-1347.
13. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105(7):788-793.
14. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007, 49(10):1015-1026.
15. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008, 15(8):715-738.
16. Annex BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005, 65(3):649-655.
17. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009, 105(8):724-736.
18. Idris NM, Haider H, Goh MW, Sim EK. Therapeutic angiogenesis for treatment of peripheral vascular disease. Growth Factors 2004, 22(4):269-279.
19. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opinion Cardiol 2007, 22(5):458-463.
20. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003, 2(11):863-871.
21. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008, 118(1):9-16.
22. Uchida C, Haas TL. Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des 2009, 15(4):411-421.
23. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000, 101(2):118-121.
24. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001, 142(5):872-880.
25. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, et al. Safety and feasibility of catheterbased local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107(21):2677-2683.
26. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006, 13(21):1503-1511.
27. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005, 45(7):982-988.
28. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009, 17(6):1109-1115.
29. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97(12):1114-1123.
30. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000, 132(11):880-884.
31. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001, 104(7):753-755.
32. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002, 90(5):512-516.
33. Mitchell R, Annex BH. Progenitor cell mobilization observed in subjects with critical limb ischemia treated with ZFP therapeutic. In: ISCT (International Society for Cellular Therapy) Meeting. Miami, FL, 2008.
34. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002, 6(1):127-133.
35. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006, 17(6):683-691.
36. Creager MA, Olin J, Belch J, Moneta G, Henry T, et al. A randomized, double-blind, placebocontrolled, parallel-group, study of Ad2/hypoxia inducible factor (HIF)-1(/VP16 in patients with intermittent claudication. In: ACC09 (American Conference of Cardiologists Scientific Sessions 2009). Orlando, FL: 2009.
37. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 2009, 28(2):14-31.
38. Lloyd PG, Prior BM, Yang HT, Terjung RL. Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. Am J Physiol Heart Circ Physiol 2003, 284(5):H1668-H1678.
39. Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, et al. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 2004, 174(1):111-120.
40. Faeder JR, Blinov ML, Hlavacek WS. Rule-based modeling of biochemical systems with BioNetGen. Methods Mol Biol 2009, 500:113-167.
41. Moraru, II, Schaff JC, Slepchenko BM, Blinov ML, Morgan F, et al. Virtual Cell modelling and simulation software environment. IET Syst Biol 2008, 2(5):352-362.
42. Keating SM, Bornstein BJ, Finney A, Hucka M. SBML Toolbox: an SBML toolbox for MATLAB users. Bioinformatics 2006, 22(10):1275-1277.
43. Takahashi K, Ishikawa N, Sadamoto Y, Sasamoto H, Ohta S, et al. E-Cell 2: multi-platform E-Cell simulation system. Bioinformatics 2003, 19(13):1727-1729.
44. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380(6573):435-439.
45. Ferrara N, Carver-Moore K, Chen H, DowdM, Lu L, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380(6573):439-442.
46. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 2000, 127(18):3941-3946.
47. Qutub AA, Popel AS. A computationalmodel of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. J Cell Sci 2006, 119(Pt 16):3467-3480.
48. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995, 270(3):1230-1237.
49. Qing G, SimonMC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009, 19(1):60-66.
50. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002, 13(1):29-37.
51. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008, 15(4):628-634.
52. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451(7181):1008-1012.
53. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, et al. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004, 64(5):1765-1772.
54. O'Hagan KA, Cocchiglia S, Zhdanov AV, Tambuwala MM, Cummins EP, et al. PGC-1alpha is coupled to HIF-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc Natl Acad Sci U S A 2009, 106(7):2188-2193.
55. Fruttiger M. VEGF gene regulation. In: Ruhrberg C, ed. VEGF in Development. Austin, Texas: Landes Bioscience; 2008, 30-39.
56. Cherwek DH, Hopkins MB, Thompson MJ, Annex BH, Taylor DA. Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. Am J Physiol Heart Circ Physiol 2000, 279(3):H932-H938.
57. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007, 249(2):133-142.
58. Aronowski J, Labiche LA. Perspectives on reperfusion-induced damage in rodent models of experimental focal ischemia and role of gammaprotein kinase C. ILAR J 2003, 44(2):105-109.
59. Chalothorn D, Clayton JA, Zhang H, Pomp D, Faber JE. Collateral density, remodeling, and VEGFA expression differ widely between mouse strains. Physiol Genomics 2007, 30(2):179-191.
60. Dokun AO, Keum S, Hazarika S, Li Y, Lamonte GM, et al. A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation 2008, 117(9):1207-1215.
61. Helisch A, Wagner S, Khan N, Drinane M, Wolfram S, et al. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol 2006, 26(3):520-526.
62. Majid A, He YY, Gidday JM, Kaplan SS, Gonzales ER, et al. Differences in vulnerability to permanent focal cerebral ischemia among 3 common mouse strains. Stroke 2000, 31(11):2707-2714.
63. Sugimori H, Yao H, Ooboshi H, Ibayashi S, Iida M. Krypton laser-induced photothrombotic distal middle cerebral artery occlusion without craniectomy in mice. Brain Res 2004, 13(3):189-196.
64. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007, 101(9):948-956.
65. Pajusola K, Kunnapuu J, Vuorikoski S, Soronen J, Andre H, et al. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. Faseb J 2005, 19(10):1365-1367.
66. Kajiwara H, Luo Z, Belanger AJ, Urabe A, Vincent KA, et al. A hypoxic inducible factor-1 alpha hybrid enhances collateral development and reduces vascular leakage in diabetic rats. J Gene Med 2009, 11(5):390-400.
67. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004, 110(16):2467-2475.
68. Li Y, Hazarika S, XieD, PippenAM, Kontos CD, et al. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 2007, 56(3):656-665.
69. Yu J, Lei L, Liang Y, Hinh L, Hickey RP, et al. An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. Faseb J 2006, 20(3):479-481.
70. Loinard C, Ginouves A, Vilar J, Cochain C, Zouggari Y, et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 2009, 120(1):50-59.
71. Dayan F, Monticelli M, Pouyssegur J, Pecou E. Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. J Theor Biol 2009, 259(2):304-316.
72. Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, et al. Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol Biol Cell 2004, 15(7):3042-3052.
73. Qutub A, Popel A. Reactive oxygen species regulate hypoxia-inducible factor HIF1alpha differentially in cancer and ischemia. Mol Cell Biol 2008, 28:5106-5119.
74. Qutub AA, Popel AS. Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. Biochim Biophys Acta 2007, 1773(10):1511-1525.
75. Yucel MA, Kurnaz IA. An in silico model for HIFalpha regulation and hypoxia response in tumor cells. Biotechnol Bioeng 2007, 97(3):588-600.
76. Ji JW, Mac Gabhann F, Popel AS. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am J Physiol Heart Circ Physiol 2007, 293:H3740-H3749.
77. Mac Gabhann F, Ji JW, Popel AS. Computational model of VEGF spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol 2006, 2(9):e127.
78. Mac Gabhann F, Ji JW, Popel AS. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng 2007, 35(6):982-994.
79. Mac Gabhann F, Ji JW, Popel AS. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol 2007, 102(2):722-734.
80. Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR1, VEGFR2 and Neuropilin in vivo: A computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 2007, 292(1):H459-H474.
81. Kong HJ, Kim ES, Huang YC, Mooney DJ. Design of biodegradable hydrogel for the local and sustained delivery of angiogenic plasmid DNA. Pharm Res 2008, 25(5):1230-1238.
82. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2008, 2:77.
83. Wu FTH, StefaniniMO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One 2009, 4(4):e5108.
84. WuFTH, StefaniniMO, Mac Gabhann F, Kontos CD, Annex BH, et al. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silicomodel. PhysiolGenomics 2009, 38(1):29-41.
85. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy? Nat Rev 2008, 8(12):942-956.
86. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003, 9(7):936-943.
87. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286(1):H153-H164.
88. Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 2008, 52(5):387-393.
89. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270(5241):1500-1502.
90. Helm CL, Fleury ME, Zisch AH, Boschetti F, Swartz MA. Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc Natl Acad Sci U S A 2005, 102(44):15779-15784.
91. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169(4):681-691.
92. Yang F, Cho SW, Son SM, Bogatyrev SR, Singh D, et al. Regenerative medicine special feature: genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci U S A 2009.
93. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7(5):359-371.
94. ShibuyaM, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5):549-560.
95. Bentley K, Mariggi G, Gerhardt H, Bates PA. Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis. PLoS Comput Biol 2009, 5(10):e1000549.
96. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 2009, 37(Pt 6):1233-1236.
97. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 2005, 437(7057):426-431.
98. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006, 174(4):593-604.
99. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004, 113(4):516-527.
100. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009, 100(6):865-869.
101. Ramsauer M, D'Amore PA. Contextual role for angiopoietins and TGFbeta1 in blood vessel stabilization. J Cell Sci 2007, 120(Pt 10):1810-1817.
102. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456(7223):809-813.
103. Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, et al. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009, 4(4):e5149.
104. Cao L, Arany PR, Wang YS, Mooney DJ. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 2009, 30(25):4085-4093.
105. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 2007, 5(3):590-598.